# Syncona Limited freeline files registration statement for proposed IPO in the United States

- Link: https://www.directorstalkinterviews.com/syncona-limited-freeline-files-registration-statement-for-proposed-ipo-in-the-united-states/412844238
- Published: 2020-07-20T07:24:11+01:00
- Author: Giles Arbor

**Syncona Ltd** (LON:SYNC), a leading healthcare company focused on founding, building
and funding a portfolio of global leaders in life science, has noted that its portfolio
company, Freeline Therapeutics Holdings plc has filed a registration statement on
Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed
initial public offering in the United States of its American Depositary Shares, 
each representing one ordinary share.

All ADSs to be sold in the proposed IPO will be offered by Freeline. Freeline has
applied to list its ADSs on The Nasdaq Global Select Market under the ticker symbol“
FRLN”. The number of ADSs to be offered and the pricing terms for the proposed IPO
have not yet been determined. The offering is subject to market conditions, and 
there can be no assurance as to whether, or when, the offering may be completed 
or as to the actual size or terms of the offering.

The Registration Statement relating to the ADSs has been filed with the SEC but 
has not yet become effective. The ADSs may not be sold nor may offers to buy be 
accepted prior to the time the Registration Statement becomes effective.

The Registration Statement can be accessed through the SEC’s EDGAR database and 
contains further information relating to Freeline.

This announcement does not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale would be unlawful 
prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means 
of a prospectus. When available, copies of the preliminary prospectus can be obtained
from any of the joint book-running managers for the offering, J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014; or Evercore Group L.L.C. at Attention: Equity Capital
Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com.

Syncona Limited is a leading FTSE250 healthcare company focused on founding, building
and funding a portfolio of global leaders in life science. Our vision is to build
a sustainable, diverse portfolio of 15 – 20 companies focused on delivering transformational
treatments to patients in truly innovative areas of healthcare, through which we
are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We take a long-term view, underpinned 
by a strategic capital base which provides us with control and flexibility over 
the management of our portfolio. We focus on delivering dramatic efficacy for patients
in areas of high unmet need.

Share on: